Full-Time
Associate Research Scientist
Accelerates antibody drug discovery with data science
Junior, Mid
Vancouver, BC, Canada
- Generating pharmacokinetic and pharmacodynamic data from biological samples to critically assess therapeutic antibody programs
- Performing ELISA, MSD and other molecular biology assays on study samples with a high degree of efficiency and accuracy
- Developing new bioanalytical methods and optimizing workflows for the detection of antibody therapeutics, or their effects, in biological samples
- Collaborating with teammates to solve problems, analyze, interpret and communicate data
- Growing your technical skill set and engaging in professional development
- Supporting laboratory management including keeping inventory of consumables and reagents
- Overseeing sample management including sample receipt, organization, and archiving
- You are excited about the opportunity to learn and apply new lab techniques in a drug development setting
- You enjoy a fast-paced work environment and are a creative problem solver who believes in teamwork to tackle the most challenging problems
- You are comfortable working independently to identify project needs then following that up by collaboratively constructing and implementing solutions
- MSc in a relevant field, or BSc plus at least 2-3 years work experience in an industrial or academic wet lab environment
- Hands on experience with ELISA or plate based assays is preferred
- Exceptional analytical and problem-solving capabilities
- Excellent documentation, organizational and communication skills
- Strong interpersonal skills with the ability to work collaboratively as a member of a cross-functional team
- Experience with molecular biology techniques like qPCR and Western Blotting
- Experience handling blood or tissue specimens
AbCellera stands out as a leader in the biotech industry due to its unique approach to antibody drug discovery, combining expert teams, advanced technology, and data science to expedite the process from target to clinic across various therapeutic areas. The company's competitive edge lies in its ability to enable swift progress, cost reduction, and problem-solving in drug development for both innovative biotechs and leading pharmaceutical companies. Furthermore, AbCellera's commitment to technical innovation is evident in its recent presentation of new data on two T-Cell Engager Programs at SITC 2023, demonstrating its active role in advancing the field.
Company Stage
Series A
Total Funding
$393.1M
Headquarters
Vancouver, Canada
Founded
2012